Analysis Hester Biosciences Limited (HESTERBIO)
6/4/2024
Analysis of Hester Biosciences Limited (HESTERBIO)
Hester Biosciences Limited has shown a consistent uptrend in its stock price over the past few days. The Relative Strength Index (RSI) values have been consistently above 60, indicating a strong bullish momentum. The Moving Average Convergence Divergence (MACD) indicator has also been positive, with the MACD line consistently above the signal line.The stock price has been trading above both the Simple Moving Average (SMA) and Exponential Moving Average (EMA), indicating a bullish trend. The Weighted Moving Average (WMA) has also been showing an upward trend.
Overall, based on the technical indicators, Hester Biosciences Limited appears to be in a strong bullish phase with potential for further price appreciation. However, investors should always consider other factors such as market conditions, company fundamentals, and external events before making any investment decisions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results, ending on February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at the time. However, on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provides a comprehensive overview of the financial and stock-related metrics for a specific company. Here are the key points:1. **Financials**:
- **Cash Flow**: Operating cash flow for the trailing twelve months (TTM) is $110,563,000,320, and levered free cash flow TTM is $84,726,874,112.
- **Balance Sheet**: Total cash on a quarterly basis is $67,150,000,128, total debt on a quarterly basis is $104,590,000,128, current ratio is 1.037, book value per share is $4.837, total cash per share is $4.379, and total debt to equity ratio is 140.968.
- **Profit Margin**: The profit margin is 26.306%.
- **Income Statement**: EBITDA is $131,393,000,000, revenue TTM is $381,623,009,280, diluted EPS TTM is $6.43, gross profit TTM is $169,148,000,000, revenue per share TTM is $24.537, net income to common TTM is $100,389,003,264, quarterly revenue growth is -4.3%, and quarterly earnings growth year-over-year is -2.2%.
- **Operating Margin**: The operating margin is 30.743%.
- **Return on Assets and Equity**: Return on assets TTM is 22.073% and return on equity TTM is 147.25%.
2. **Stock Statistics**:
- **Short Interest**: Short ratio is 1.53, float shares are 15,308,320,742, shares short are 99,287,450, average 10-day volume is 46,860,048, average 90-day volume is 57,498,254, shares outstanding are 15,334,099,968, percent held by insiders is 5.22%, percent held by institutions is 57.589%, and short percent of shares outstanding is 0.65%.
3. **Valuations Metrics**:
- **Ratios**: PEG ratio is 26.319502, forward PE is 26.319502, trailing PE is 29.59409, price to book ratio MRQ is 39.3405, price to sales TTM is 7.646095, enterprise value is $2,950,762,332,160, enterprise to EBITDA ratio is 22.763, enterprise to revenue ratio is 7.732, and market capitalization is $2,917,925,650,432.
4. **Stock Price Summary**:
- **Market Performance**: Beta is 1.264, 50-day moving average is $176.2646, 200-day moving average is $181.0429, 52-week low is $164.08, 52-week high is $199.62, and 52-week change is 6.853%.
5. **Dividends and Splits**:
- **Dividend Information**: Payout ratio is 14.93%, dividend date is May 16, 2024, last split date is August 31, 2020 (4-for-1 split), ex-dividend date is May 10, 2024, forward annual dividend rate is $1, 5-year average dividend yield is 0.73%, forward annual dividend yield is 0.5255%, trailing annual dividend rate is $0.97, and trailing annual dividend yield is 0.5097%.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25. This indicates a moderate growth in sales for the current quarter.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25. This suggests a further increase in sales for the next quarter.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38. This indicates a steady but modest growth in annual sales for the current fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a significant sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38. This suggests a more substantial growth in sales for the next fiscal year.
Overall, the estimates indicate a positive trend of increasing sales for both the upcoming quarters and the next fiscal year, with varying degrees of growth expected.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
Overall, it appears that the company has experienced a significant growth rate in the past 5 years, but analysts are forecasting a slightly lower growth rate for the next 5 years. However, there is still expected growth in the upcoming periods based on the consensus estimates.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the majority clustering around the median and average values. The current price is below both the median and average forecast, indicating that analysts generally expect the price to increase in the future. However, it's important to note that these are just forecasts and actual market conditions may vary.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the past four fiscal years.
2. The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) has also shown a positive trend, indicating operational efficiency.
3. Net income has been growing consistently, reflecting the company's profitability.
4. Despite fluctuations in other income and expenses, the company has managed to maintain a strong financial performance.
5. The basic and diluted earnings per share have remained relatively stable over the years.
6. The company has effectively managed its operating expenses in relation to its revenue growth.
7. The non-operating interest expenses have been relatively stable, indicating a consistent financial strategy.
8. The company has been able to generate a positive EBIT (Earnings Before Interest and Taxes) each year, showing operational profitability.
9. The gross profit margin has been maintained, suggesting effective cost management.
10. Overall, the financial performance of the company, as indicated by its revenue figures, has been positive and shows a consistent growth trajectory.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown fluctuations but has generally been on an upward trend.
6. The company has been managing its short-term and long-term debts while investing in non-current assets for future growth.
7. Accumulated depreciation has been significant, affecting the value of non-current assets.
8. The company has been retaining earnings and issuing common stock to strengthen shareholders' equity.
9. Provision for risks and charges has been maintained to cover potential future liabilities.
10. Overall, the company's financial position seems stable and geared towards growth.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its peak in 2020 and its lowest point in 2022.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, but there are fluctuations that may require further analysis to understand the underlying reasons.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This is also an improvement from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current year ending on September 30, 2024, the average EPS estimate is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This indicates growth from the EPS of $5.67 for the previous year.
4. For the next year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests further growth compared to the EPS of $6.10 for the current year.
Overall, the analysts' estimates show a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
MACD of HESTERBIO
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
